Diabetes drug (MSDC-0160) slows Parkinson’s progression in lab models
Why is it important?
- Novelty 100% 100%
- Proximity 60% 60%
- Deliverability 100% 100%
Other things to know
- MSDC-0160 is an investigational drug, meaning it is not currently approved for use to treat Parkinson’s
- A clinical trial is in development but is not yet open.
- MSDC-0160 vs Pioglitozone (a similar drug previously tested in Parkinson’s) looking at target interaction
- MSDC-0160 plus Exenatide (another diabetes treatment which has shown potential disease modifying effects in Parkinson’s)
The goal of this ongoing work is to determine the level of interaction of MSDC-0160 with its target protein MPC and to understand if the combination of MSDC-0160 and Exenatide can change the course of the disease more potently than either drug alone. Positive results from this research would provide key supporting evidence to move MSDC-0160 into a clinical trial.
Another type 2 diabetes target (the GLP-1 receptor) has also been shown to be of relevance in Parkinson’s. Activation of GLP-1 receptors in the pancreas stimulates insulin release however GLP-1 receptors are also found throughout the brain and activation of such receptors has been shown to improve dopamine neuron function, reduce inflammation, switch on cell survival signals and help improve energy production in models of Parkinson’s.
A recent trial of Exenatide for Parkinson’s has shown promise in slowing the progression of Parkinson’s and two further trials using similar drugs, liraglutide and lixsenatide are being currently underway. More information about these trials can be found on the CPT website.
If you are interested in taking part in a clinical trial near you, take a look at Fox Trial Finder.